KURA

Kura Oncology Inc

10.56

Oct 29 • 3:59 PM ET -0.16 (-1.49%)

10.51

Aftermarket • 7:30 PM ET -0.05 (-0.47%)

Healthcare Biotechnology USA Small NASD

Peers: SNDX RIGL DMRA AAPG GERN SLS INCY EXEL ABBV ATNM

| Held by: VTI XBI IWM VXF IWO IBB FESM VTWO SCHA IDNA

Scroll to Statements

Index	RUT
Market Cap	939.42M
Enterprise Value	444.85M
Income	-296.77M
Sales	77.22M
Book/sh	0.54
Cash/sh	5.83
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	260
IPO	Sep 16, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	12.17
P/B	19.40
P/C	1.81
P/FCF	-
EV/EBITDA	-
EV/Sales	5.76
Quick Ratio	4.71
Current Ratio	4.73
Debt/Eq	0.50
LT Debt/Eq	0.39
Option/Short	Yes / Yes

EPS (ttm)	-3.36
EPS next Y	-2.42
EPS next Q	-0.82
EPS this Y	-2.04%
EPS next Y	25.37%
EPS next 5Y	15.30%
EPS past 3/5Y	-16.16% -13.48%
Sales past 3/5Y	- -
EPS Y/Y TTM	-48.89%
Sales Y/Y TTM	-7.27%
EPS Q/Q	-1.87%
Sales Q/Q	36.54%
Earnings	Aug 12 AMC
EPS/Sales Surpr.	12.23% 3.53%

Insider Own	2.78%
Insider Trans	-2.12%
Inst Own	100.68%
Inst Trans	3.50%
ROA	-46.73%
ROE	-167.71%
ROIC	-440.46%
Gross Margin	97.60%
Oper. Margin	-411.90%
Profit Margin	-384.30%
SMA20	4.71%
SMA50	-5.56%
SMA200	7.74%
Trades

Shs Outstand	88.95M
Shs Float	86.49M
Short Float	16.56%
Short Ratio	7.66
Short Interest	14.32M
52W High	13.90 -24.03%
52W Low	7.36 43.53%
Volatility	5.64% 4.98%
ATR (14)	0.52
RSI (14)	53.34
Beta	0.55
Rel Volume	0.85
Avg Volume	1.87M
Volume	1,590,517

Perf Week	7.10%
Perf Month	-1.40%
Perf Quarter	17.20%
Perf Half Y	19.59%
Perf YTD	1.64%
Perf Year	2.92%
Perf 3Y	37.86%
Perf 5Y	-35.69%
Perf 10Y	142.76%
Recom	1.19
Target Price	31.85
Prev Close	10.72
Price	10.56
Change %	-1.49%

Consensus

Strong Buy

Avg. Price Target

$31.85

Implied Upside

+201.6%

Analysts15incl. previous ratings

Rating Distribution10 Buy · 5 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 01, 2026	Initiated	JJP Morgan	Overweight	$30	+184.1%
Apr 14, 2026	Initiated	LLake Street	Buy	$23	+117.8%
Sep 04, 2025	Initiated	GGuggenheim	Neutral
Feb 06, 2025	Downgrade	BBTIG Research	Buy → Neutral
Oct 24, 2024	Initiated	UUBS	Buy	$27	+155.7%
Oct 14, 2024	Downgrade	SStifel	Buy → Hold	$26 → $19	+79.9%
Dec 22, 2023	Initiated	MMizuho	Buy	$26	+146.2%
Aug 11, 2023	Initiated	BBofA Securities	Buy	$31	+193.6%
Jul 27, 2023	Initiated	BScotiabank	Sector Perform	$10.50	-0.6%
May 17, 2023	Initiated	BBTIG Research	Buy	$31	+193.6%
Jan 31, 2023	Initiated	SStifel	Buy	$25	+136.7%
Jul 12, 2022	Initiated	CCantor Fitzgerald	Overweight	$30	+184.1%
Feb 15, 2022	Initiated	JJefferies	Buy	$35	+231.4%
May 05, 2021	Resumed	CCredit Suisse	Outperform	$42	+297.7%
Apr 26, 2021	Resumed	CCredit Suisse	Outperform	$42	+297.7%
Dec 07, 2020	Reiterated	HH.C. Wainwright	Buy	$40 → $45	+326.1%
Dec 03, 2020	Initiated	SStifel	Buy	$45	+326.1%
Nov 05, 2020	Downgrade	PPiper Sandler	Overweight → Neutral
Jul 07, 2020	Initiated	CCredit Suisse	Outperform	$27	+155.7%
May 05, 2020	Initiated	BBarclays	Overweight	$24	+127.3%

Oct-13-26 07:30AM	Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes (GlobeNewswire) -5.44%
Oct-07-26 07:15AM	Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in Diabetes (GlobeNewswire)
Oct-02-26 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-29-26 08:27AM	Caspian Therapeutics and Kura Oncology Report Preclinical Data for Diabetes Candidate KO-7246 (InvestorsHub)
05:15AM	Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes (GlobeNewswire)
11:54AM	Loading…
Sep-09-26 11:54AM	Kura spins diabetes work into a Lilly-backed biotech startup (BioPharma Dive)
07:00AM	Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes (GlobeNewswire)
Sep-08-26 07:00AM	Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer (GlobeNewswire) -5.51%
Sep-04-26 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-01-26 07:15AM	Kura Oncology to Participate in Three Investor Conferences in September (GlobeNewswire)
Aug-25-26 05:22PM	KURA Stock Hits Fresh 52-Week High As CEO Buys More Shares Retail Wonders If Wilson Is Following Moderna CEOs Playbook (Stocktwits) +9.60%
09:55AM	Kura Oncology Shares Jump After CEO Buys $1.24 Million of Stock (InvestorsHub)
Aug-17-26 06:28PM	Why Is KURA Stock Rallying 8% After-Hours? (Stocktwits) +9.31%
Aug-12-26 04:32PM	Kura Oncology: Q2 Earnings Snapshot (Associated Press)
04:02PM	Kura Oncology Reports Second Quarter 2026 Financial Results (GlobeNewswire)
08:32AM	Loading…
Aug-10-26 08:32AM	Kura Oncology Announces Publication in Blood Highlighting Ziftomenib's Differentiated Binding Profile and Preclinical Activity (GlobeNewswire)
Aug-07-26 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-05-26 07:30AM	Kura Oncology to Report Second Quarter Financial Results (GlobeNewswire)
Jul-27-26 06:32AM	Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naive Clear Cell Renal Cell Carcinoma Patients at KCRS 2026 (GlobeNewswire)
Jul-14-26 07:02AM	Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib's Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026 (GlobeNewswire)
Jul-03-26 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-11-26 08:02AM	Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML (GlobeNewswire)
Jun-05-26 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-26 06:53AM	Kura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy (GlobeNewswire)
Jun-02-26 08:32AM	Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML (GlobeNewswire)
May-26-26 06:02AM	Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors (GlobeNewswire) -7.47%
May-19-26 04:02PM	Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit (GlobeNewswire) +15.40%
May-13-26 01:02AM	Kura Oncology Inc (KURA) Q1 2026 Earnings Call Highlights: Strong KOMZIFTI Launch Amid Rising ... (GuruFocus.com)
May-12-26 04:10PM	Kura Oncology: Q1 Earnings Snapshot (Associated Press)
04:02PM	Kura Oncology Reports First Quarter 2026 Financial Results (GlobeNewswire)
09:40AM	Loading…
09:40AM	Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress (GlobeNewswire)
May-06-26 07:30AM	Kura Oncology to Participate in Bank of America Securities Healthcare Conference (GlobeNewswire)
May-05-26 07:30AM	Kura Oncology to Report First Quarter 2026 Financial Results (GlobeNewswire)
May-04-26 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.47%
Apr-17-26 06:00AM	Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib (GlobeNewswire) +8.28%
Apr-09-26 07:30AM	Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026 (GlobeNewswire)
Apr-03-26 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-06-26 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.29%
Mar-05-26 09:07PM	Kura Oncology Q4 Earnings Call Highlights (MarketBeat)
02:01PM	Kura Oncology Inc (KURA) Q4 2025 Earnings Call Highlights: KOMZIFTI Launch Boosts Revenue Amid ... (GuruFocus.com)
07:40AM	Kura Oncology (KURA) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
06:47AM	Kura Oncology: Q4 Earnings Snapshot (Associated Press Finance)
06:31AM	Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-26-26 07:30AM	Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-25-26 07:30AM	Kura Oncology to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Feb-19-26 10:00AM	Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline (Zacks)
Feb-18-26 10:00AM	Earnings Preview: Kura Oncology (KURA) Q4 Earnings Expected to Decline (Zacks)
Feb-12-26 04:04PM	1 Under-$10 Stock Set to Surge as Much as 850% in 2026 (Barchart)
Feb-06-26 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.81%
Feb-02-26 09:36AM	Analyst Flags Kura Oncology, Inc. (KURA) for 2026 Milestones and Pipeline Expansion (Insider Monkey)
Jan-21-26 04:51AM	New Strong Sell Stocks for January 21st (Zacks)
Jan-14-26 09:16AM	Kura Oncology price target lowered to $20 from $25 at Leerink (TipRanks)
Jan-11-26 05:00PM	Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones (GlobeNewswire)
Jan-05-26 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.69%
Dec-23-25 12:52AM	Jim Cramer Calls Kura Speculative But Says "It's One of the Stronger Ones I've Seen in a Very Long Time" (Insider Monkey)
Dec-21-25 10:26AM	Jim Cramer Discusses Kura Oncology as a Speculative Bet (Insider Monkey)
Dec-18-25 07:58PM	Lightning Round: Don't get involved in any 'year of magical investing' stock: Jim Cramer (CNBC TV)
Dec-15-25 11:10PM	Kura Oncology (KURA) Gains Momentum as Barclays Sees Significant Potential in Ziftomenib Approval (Insider Monkey)
Dec-08-25 10:30AM	Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML (GlobeNewswire)
Dec-04-25 12:20PM	Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points (PR Newswire)
Dec-03-25 08:32AM	Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (GlobeNewswire) +7.55%
Dec-02-25 08:02AM	First U.S. Commercial Sale of KOMZIFTI Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin (GlobeNewswire)
Nov-25-25 05:16PM	KOMZIFTI (ziftomenib) Added to National Comprehensive Cancer Network (NCCN) Guidelines for Acute Myeloid Leukemia (AML) (GlobeNewswire)
Nov-14-25 07:15AM	Kura and Kyowa Kirin secure FDA go-ahead for targeted leukaemia therapy (Pharmaceutical Technology)
06:06AM	Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal (BioPharma Dive)
Nov-13-25 10:51AM	Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia (GlobeNewswire)
Nov-12-25 04:05PM	Kura Oncology to Participate in Upcoming Investor Conference (GlobeNewswire)
Nov-07-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-04-25 04:03PM	Kura Oncology Inc (KURA) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses (GuruFocus.com)
07:45AM	Kura Oncology (KURA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
06:50AM	Kura Oncology: Q3 Earnings Snapshot (Associated Press Finance)
06:31AM	Kura Oncology Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-03-25 04:02PM	Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin (GlobeNewswire)
09:14AM	Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting (GlobeNewswire)
07:50AM	What To Expect From Kura Oncology Inc (KURA) Q3 2025 Earnings (GuruFocus.com)
Oct-28-25 04:01PM	Kura Oncology to Report Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-24-25 07:02AM	Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin (GlobeNewswire) +6.59%
Oct-18-25 03:23AM	Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress (GlobeNewswire)
Oct-03-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-01-25 07:01AM	Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) (GlobeNewswire)
Sep-29-25 04:01PM	Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML) (GlobeNewswire)
Sep-25-25 05:18PM	Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology (GlobeNewswire) +8.25%
Sep-24-25 07:30AM	Kura Oncology to Participate in Upcoming Investor Conference (GlobeNewswire)
Sep-16-25 04:01PM	Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types (GlobeNewswire)
Sep-08-25 12:30AM	LifeSci Capital Maintains Buy Rating on Kura Oncology (KURA) (Insider Monkey)
Sep-05-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-03-25 08:02AM	Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program (GlobeNewswire) +6.04%
Aug-28-25 07:30AM	Kura Oncology to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Aug-07-25 06:15PM	Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -7.05%
05:16PM	Kura Oncology: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Kura Oncology Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-06-25 07:00AM	OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee (GlobeNewswire) -5.19%
Aug-04-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-31-25 07:30AM	Kura Oncology to Report Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-03-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-12-25 08:48AM	Is the Options Market Predicting a Spike in Kura Oncology Stock? (Zacks)
07:30AM	Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bair Teresa Brophy	Chief Legal Officer	Sep 28 '26	Sale	10.50	8,442	88,618	187,002	Sep 29 06:30 PM
FORD KATHLEEN	Chief Operating Officer	Sep 28 '26	Sale	10.50	6,906	72,494	146,654	Sep 29 06:30 PM
FORD KATHLEEN	Chief Operating Officer	Sep 29 '26	Sale	10.75	3,668	39,437	142,986	Sep 29 06:30 PM
Leoni Mollie	Chief Medical Officer	Sep 29 '26	Sale	10.75	28,802	309,567	141,095	Sep 29 06:30 PM
Leoni Mollie	Chief Medical Officer	Sep 28 '26	Sale	10.50	12,448	130,670	169,897	Sep 29 06:30 PM
DOYLE THOMAS JAMES	SVP, Finance & Accounting	Sep 28 '26	Sale	10.50	4,607	48,361	142,428	Sep 29 06:30 PM
Powl Brian T.	Chief Commercial Officer	Sep 28 '26	Sale	10.53	17,020	179,183	152,249	Sep 29 06:30 PM
Powl Brian T.	Chief Commercial Officer	Sep 29 '26	Sale	10.75	15,430	165,852	136,819	Sep 29 06:30 PM
BRIAN POWL	Officer	Sep 29 '26	Proposed Sale	10.61	15,430	163,712		Sep 29 04:25 PM
MOLLIE LEONI	Officer	Sep 29 '26	Proposed Sale	10.61	28,802	305,589		Sep 29 04:25 PM
KATHLEEN FORD	Officer	Sep 29 '26	Proposed Sale	10.61	3,668	38,917		Sep 29 04:25 PM
POWL BRIAN T	Officer	Sep 28 '26	Proposed Sale	10.76	9,020	97,055		Sep 28 09:00 PM
LEONI MOLLIE	Officer	Sep 28 '26	Proposed Sale	10.76	12,448	133,940		Sep 28 08:00 PM
BAIR TERESA BROPHY	Officer	Sep 28 '26	Proposed Sale	10.76	8,442	90,836		Sep 28 08:00 PM
FORD KATHLEEN	Officer	Sep 28 '26	Proposed Sale	10.76	6,906	74,309		Sep 28 08:00 PM
DOYLE THOMAS JAMES	Officer	Sep 28 '26	Proposed Sale	10.76	4,607	49,571		Sep 28 08:00 PM
BRIAN POWL	Officer	Sep 28 '26	Proposed Sale	10.76	8,000	86,080		Sep 28 04:20 PM
Burrows Francis	Chief Scientific Officer	Sep 24 '26	Option Exercise	6.15	30,000	184,500	63,053	Sep 25 04:05 PM
Burrows Francis	Chief Scientific Officer	Sep 24 '26	Sale	10.83	20,726	224,514	42,327	Sep 25 04:05 PM
FRANCIS J BURROWS	Officer	Sep 24 '26	Proposed Sale	10.83	20,726	224,514		Sep 24 04:05 PM
WILSON TROY EDWARD	President and CEO	Aug 24 '26	Buy	12.39	100,000	1,239,000	479,194	Aug 24 05:30 PM
Powl Brian T.	Chief Commercial Officer	Aug 21 '26	Sale	11.89	4,345	51,663	169,269	Aug 24 05:30 PM
BRIAN POWL	Officer	Aug 21 '26	Proposed Sale	11.71	4,345	50,880		Aug 21 04:41 PM
Bair Teresa Brophy	Chief Legal Officer	Aug 19 '26	Sale	12.63	31,487	397,681	195,444	Aug 21 04:30 PM
TERESA BAIR	Officer	Aug 19 '26	Proposed Sale	12.33	31,487	388,235		Aug 19 04:24 PM
WILSON TROY EDWARD	President and CEO	Aug 17 '26	Buy	11.12	100,000	1,112,000	379,194	Aug 17 04:45 PM
Leoni Mollie	Chief Medical Officer	Jun 18 '26	Sale	9.82	84,929	834,283	182,345	Jun 22 06:00 PM
MOLLIE VANESSA LEONI	Officer	Jun 18 '26	Proposed Sale	9.57	84,929	812,771		Jun 18 04:23 PM
Powl Brian T.	Chief Commercial Officer	May 21 '26	Sale	11.00	10,000	110,000	173,614	May 22 04:05 PM
BRIAN POWL	Officer	May 21 '26	Proposed Sale	10.34	10,000	103,400		May 21 04:31 PM
Powl Brian T.	Chief Commercial Officer	May 19 '26	Sale	9.21	339	3,122	183,614	May 20 04:05 PM
FORD KATHLEEN	Chief Operating Officer	May 19 '26	Sale	9.08	2,257	20,483	153,560	May 20 04:05 PM
Bair Teresa Brophy	Chief Legal Officer	May 18 '26	Sale	9.38	2,256	21,160	226,931	May 20 04:05 PM
KATHLEEN FORD	Officer	May 19 '26	Proposed Sale	9.20	2,257	20,764		May 19 04:39 PM
BRIAN POWL	Officer	May 19 '26	Proposed Sale	9.20	339	3,119		May 19 04:37 PM
TERESA BAIR	Officer	May 18 '26	Proposed Sale	9.22	2,256	20,800		May 18 04:31 PM
WILSON TROY EDWARD	President and CEO	Mar 23 '26	Option Exercise	6.15	6,103	37,533	435,456	Mar 25 09:00 AM
Malley Thomas	Director	Mar 18 '26	Option Exercise	3.12	10,000	31,200	10,000	Mar 20 09:00 AM
Powl Brian T.	Chief Commercial Officer	Jan 27 '26	Sale	8.46	6,414	54,266	183,275	Jan 27 09:35 PM
FORD KATHLEEN	Chief Operating Officer	Jan 27 '26	Sale	8.46	1,813	15,339	153,560	Jan 27 09:35 PM
Leoni Mollie	Chief Medical Officer	Jan 27 '26	Sale	8.46	8,180	69,209	267,274	Jan 27 09:35 PM
DOYLE THOMAS JAMES	SVP, Finance & Accounting	Jan 27 '26	Sale	8.46	7,142	60,426	145,167	Jan 27 09:35 PM
Burrows Francis	Chief Scientific Officer	Jan 27 '26	Sale	8.46	1,311	11,092	32,424	Jan 27 09:35 PM
Bair Teresa Brophy	Chief Legal Officer	Jan 27 '26	Sale	8.46	11,208	94,828	226,931	Jan 27 09:35 PM
BAIR TERESA BROPHY	Officer	Jan 27 '26	Proposed Sale	8.47	11,208	94,932		Jan 27 09:30 PM
POWL BRIAN T	Officer	Jan 27 '26	Proposed Sale	8.47	6,414	54,327		Jan 27 09:30 PM
FORD KATHLEEN	Officer	Jan 27 '26	Proposed Sale	8.47	1,813	15,356		Jan 27 09:30 PM
LEONI MOLLIE	Officer	Jan 27 '26	Proposed Sale	8.47	8,180	69,285		Jan 27 09:30 PM
BURROWS FRANCIS	Officer	Jan 27 '26	Proposed Sale	8.47	1,311	11,104		Jan 27 09:30 PM
DOYLE THOMAS JAMES	Officer	Jan 27 '26	Proposed Sale	8.47	7,142	60,493		Jan 27 09:30 PM
Burrows Francis	Chief Scientific Officer	Dec 18 '25	Option Exercise	4.80	35,000	168,000	57,461	Dec 19 04:30 PM
Burrows Francis	Chief Scientific Officer	Dec 18 '25	Sale	9.78	23,726	231,931	33,735	Dec 19 04:30 PM
FRANCIS J BURROWS	Officer	Dec 18 '25	Proposed Sale	9.78	23,726	231,934		Dec 18 04:07 PM
Hasnain Faheem	Director	Dec 09 '25	Option Exercise	3.12	10,000	31,200	33,983	Dec 10 04:05 PM
Hasnain Faheem	Director	Dec 09 '25	Sale	10.98	10,000	109,764	23,983	Dec 10 04:05 PM
FAHEEM HASNAIN	Director	Dec 09 '25	Proposed Sale	11.64	10,000	116,400		Dec 09 04:23 PM
Bair Teresa Brophy	Chief Legal Officer	Nov 14 '25	Sale	11.18	8,804	98,401	188,139	Nov 14 08:00 PM
Powl Brian T.	Chief Commercial Officer	Nov 14 '25	Sale	11.18	8,887	99,329	139,689	Nov 14 08:00 PM
Leoni Mollie	Chief Medical Officer	Nov 14 '25	Sale	11.18	15,485	173,074	225,454	Nov 14 08:00 PM
DOYLE THOMAS JAMES	SVP, Finance & Accounting	Nov 14 '25	Sale	11.18	4,539	50,732	130,257	Nov 14 08:00 PM
FORD KATHLEEN	Officer	Nov 14 '25	Proposed Sale	10.68	6,902	73,713		Nov 14 08:00 PM
DOYLE THOMAS JAMES	Officer	Nov 14 '25	Proposed Sale	10.68	4,539	48,477		Nov 14 08:00 PM
FORD KATHLEEN	Chief Operating Officer	Nov 14 '25	Sale	11.18	6,902	77,143	105,373	Nov 14 08:00 PM
LEONI MOLLIE	Officer	Nov 14 '25	Proposed Sale	10.68	15,485	165,380		Nov 14 08:00 PM
POWL BRIAN T	Officer	Nov 14 '25	Proposed Sale	10.68	8,887	94,913		Nov 14 08:00 PM
BAIR TERESA BROPHY	Officer	Nov 14 '25	Proposed Sale	10.68	8,804	94,027		Nov 14 08:00 PM

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Ph.D.Dr. Troy Edward Wilson J.D.

Chief Operating OfficerMs. Kathleen Ford

M.S.Mr. Brian T. Powl M.B.A.

Chief Financial OfficerMs. Jennifer Fulk

Senior Vice President of Finance & AccountingMr. Thomas Doyle

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KURA

Kura Oncology Inc

Upgrade your Finviz experience